Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Inactivation of tumor-infiltrating lymphocytes (TIL) is one of the mechanisms mitigating antitumor immunity during tumor onset and progression. Epigenetic abnormalities are regarded as a major culprit contributing to the dysfunction of TILs within tumor microenvironments. In this study, we used a murine model of melanoma to discover that Tet2 inactivation significantly enhances the antitumor activity of TILs with an efficacy comparable to immune checkpoint inhibition imposed by anti-PD-L1 treatment. Single-cell RNA-sequencing analysis suggested that Tet2-deficient TILs exhibit effector-like features. Transcriptomic and ATAC-sequencing analysis showed that Tet2 ablation reshapes chromatin accessibility and favors binding of transcription factors geared toward CD8+ T-cell activation. Furthermore, the ETS family of transcription factors contributed to augmented CD8+ T-cell function following Tet2 depletion. Overall, our study establishes that Tet2 constitutes one of the epigenetic barriers that account for dysfunction of TILs and that Tet2 inactivation could promote antitumor immunity to suppress tumor growth. Significance: This study suggests that ablation of TET2+ from TILs could promote their antitumor function by reshaping chromatin accessibility for key transcription factors and enhancing the transcription of genes essential for antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
ATAC-seq: a method for assaying chromatin accessibility genome-wide
Buenrostro, J. D., Wu, B., Chang, H. Y., & Greenleaf, W. J. (2015) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb2129s109 · Cited by 3,289
Chromatin accessibility and the regulatory epigenome
Klemm, S. L., Shipony, Z., & Greenleaf, W. J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0089-8 · Cited by 1,793 · cited 1×
“Because chromatin accessible regions are known to be critical for TF binding (34), we analyzed the enrichment of TF motifs within the identified WT- or Tet2-specific differential accessible regions (Fig.”
BackgroundMutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · cited 1×
“TET2 is one of the frequently mutated genes in the hematopoietic and immune systems and is a well-known tumor suppressor (15, 17).”
BackgroundClonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536 · cited 1×
“Indeed, recent 453 studies have shown that CH-associated Tet2 loss-of-function in HSPCs accelerates atherosclerosis 454 due to the increased inflammasome activity in Tet2-deficient macrophages (37).”
BackgroundTET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity
Williams, K., Christensen, J., Pedersen, M. T., Johansen, J. V., Cloos, P. A. C., Rappsilber, J., & Helin, K. (2011) · Nature · doi:10.1038/nature10066 · Cited by 1,021
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933 · cited 3×
“50 51 Introduction 52 Dynamic epigenetic alterations have been observed in CD8+ tumor infiltrating lymphocytes (TILs) 53 during tumor progression (1,2).”
BackgroundDisruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862 · cited 3×
“infiltrating myeloid cells (13,14) improves immunotherapy efficiency, suggesting the beneficial effects 75 of TET2 inactivation during anti-tumor immunotherapy.”
BackgroundRecurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Busque, L., Patel, J. P., Figueroa, M. E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2413 · Cited by 830
Self-citationTet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807 · cited 3×
“In addition to changes in chromatin accessibility arising from Tet2 depletion in CD8þ TILs, Tet2 loss might abrogate its interaction with negative regulators of gene transcription, such as Sin3a (38) and Hdac2 (20), thereby contributing to augmented transcriptional activation in Tet2 deficient cells.”
Background
Cited by
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 259
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
“Many tumors express PD-1 receptor ligands, such as PD-L1, permitting the mitigation of anti-tumor immunity (153, 154).”
BackgroundMechanisms of T cell exhaustion guiding next-generation immunotherapy
Zebley, C. C., & Youngblood, B. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.004 · Cited by 65
Herbrich, S., Chaib, M., Anandhan, S., Andrewes, S. W., Nagarajan, A., Guan, B., Gandhi, N., Gilliam, J., Radovich, M., & Sharma, P. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.09.011 · Cited by 30
Metadata
- Authors
- Lee, M., Li, J., Li, J., Fang, S., Zhang, J., Vo, A. T. T., Han, W., Zeng, H., Isgandarova, S., Martinez-Moczygemba, M., Zhou, Y., Sun, D., & Huang, Y.
- Venue
- Cancer Research
- Published
- 2021-02-15
- Volume
- 81
- Issue
- 8
- Pages
- 1965-1976
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W3130706708
- Cited by
- 49
- References
- 16
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes. https://app.cochat.ai/papers/10.1158/0008-5472.can-20-3213
- The paper
- Lee, M., Li, J., Li, J., Fang, S., Zhang, J., Vo, A. T. T., Han, W., Zeng, H., Isgandarova, S., Martinez-Moczygemba, M., Zhou, Y., Sun, D., & Huang, Y. (2021). Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes. Cancer Research. https://doi.org/10.1158/0008-5472.can-20-3213
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.